SCHEDULE: Bellevue Group AG Discloses Significant Passive Stake in MacroGenics, Inc.

Bellevue Group AG and its subsidiary Bellevue Asset Management AG have disclosed a 15.7% passive ownership stake in MacroGenics, Inc., holding 9,929,963 shares of common stock.

Summary

• Bellevue Group AG, on behalf of its wholly-owned subsidiary Bellevue Asset Management AG, has filed a Schedule 13G with the SEC.
• The reporting persons collectively beneficially own 9,929,963 shares of MacroGenics, Inc. Common Stock.
• This ownership represents 15.7% of the total class of securities.
• Bellevue Group AG and Bellevue Asset Management AG hold shared voting power and shared dispositive power over all 9,929,963 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of MacroGenics, Inc.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a reputable financial institution is generally viewed positively as it signals confidence in the issuer, although it provides no operational or financial performance details.

Positives

• Bellevue Group AG, a Swiss financial institution, has taken a substantial 15.7% stake in MacroGenics, Inc., indicating significant institutional confidence in the company.
• The investment is classified as passive, suggesting a long-term holding strategy without immediate intent to influence control, which can be viewed as a stable investment.

Negatives

• No specific negative information is disclosed in this Schedule 13G filing, as it pertains solely to an ownership disclosure.

Risks

• The filing itself does not detail specific operational or financial risks of MacroGenics, Inc.
• The investment is passive, meaning Bellevue Group AG does not intend to influence or change control of MacroGenics, Inc., which might limit their ability to intervene if the company faces significant challenges.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance from MacroGenics, Inc. It is an ownership disclosure by an investor.

Management Comments

• Bellevue Group AG and Bellevue Asset Management AG certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of MacroGenics, Inc.

Industry Context

The filing reflects a significant institutional investment in a publicly traded company, a common occurrence in the financial markets where large asset managers acquire substantial stakes for portfolio diversification or strategic investment. This type of disclosure provides transparency regarding significant ownership positions.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be perceived positively, potentially boosting investor confidence and liquidity.
• Management: Awareness of a significant passive investor, though without direct control influence, may influence strategic considerations.

Next Steps

• No specific future actions or milestones for MacroGenics, Inc. are mentioned in this ownership disclosure.

Key Dates

Keywords

MacroGenics, Bellevue Group AG, Bellevue Asset Management AG, Schedule 13G, common stock, beneficial ownership, institutional investment, passive investment, biotechnology